Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II Hexokinase

For more than two-thirds of this century we have known that one of the most common and profound phenotypes of cancer cells is their propensity to utilize and catabolize glucose at high rates. This common biochemical signature of many cancers, particularly those that are poorly differentiated and proliferate rapidly, has remained until recently a “metabolic enigma.” However, with many advances in the biological sciences having been applied to this problem, cancer cells have begun to reveal their molecular strategies in maintaining an aberrant metabolic behavior. Specifically, studies performed over the past two decades in our laboratory demonstrate that hexokinase, particularly the Type II isoform, plays a critical role in initiating and maintaining the high glucose catabolic rates of rapidly growing tumors. This enzyme converts the incoming glucose to glucose-6-phosphate, the initial phosphorylated intermediate of the glycolytic pathway and an important precursor of many cellular “building blocks.” At the genetic level the tumor cell adapts metabolically by first increasing the gene copy number of Type II hexokinase. The enzyme's gene promoter, in turn, shows a wide promiscuity toward the signal transduction cascades active within tumor cells. It is activated by glucose, insulin, low oxygen “hypoxic” conditions, and phorbol esters, all of which enhance the rate of transcription. Also, the tumor cell uses the tumor suppressor p53, which is usually modified by mutations to debilitate cell cycle controls, to further activate hexokinase gene transcription. This results in both enhanced levels of the enzyme, which binds to mitochondrial porins thus gaining preferential access to mitochondrially generated ATP, and in a decreased susceptibility to product inhibition and proteolytic degradation. Significantly, these multiple strategies all work together to enable tumor cells to develop a metabolic strategy compatible with rapid proliferation and prolonged survival.

[1]  O. Greengard,et al.  The dedifferentiated pattern of enzymes in livers of tumor-bearing rats. , 1972, Cancer research.

[2]  P. Pedersen,et al.  Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. , 1988, The Journal of biological chemistry.

[3]  P. Pedersen,et al.  Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells. , 1984, Cancer research.

[4]  H. Terada,et al.  Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130 , 1991, FEBS letters.

[5]  J. Wilson,et al.  Complete amino acid sequence of the type II isozyme of rat hexokinase, deduced from the cloned cDNA: comparison with a hexokinase from novikoff ascites tumor. , 1991, Archives of biochemistry and biophysics.

[6]  P. Pedersen,et al.  Glucose catabolism in cancer cells: regulation of the type II hexokinase promoter by glucose and cyclic AMP , 1996, FEBS letters.

[7]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells. , 1995, The Journal of Biological Chemistry.

[8]  B. Nelson,et al.  Evidence that transcription of the hexokinase gene is increased in a rapidly growing rat hepatoma. , 1985, Biochemical and biophysical research communications.

[9]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[10]  P. Pedersen,et al.  Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. , 1988, Cancer research.

[11]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[12]  D. Mayer,et al.  Differences in expression and intracellular distribution of hexokinase isoenzymes in rat liver cells of different transformation stages. , 1994, Biochimica et biophysica acta.

[13]  P. Pedersen,et al.  Hexokinase receptor complex in hepatoma mitochondria: evidence from N,N'-dicyclohexylcarbodiimide-labeling studies for the involvement of the pore-forming protein VDAC. , 1986, Biochemistry.

[14]  T. Sugimura,et al.  Hexokinase isozyme patterns of human uterine tumors , 1972, Cancer.

[15]  S. Weinhouse Glycolysis, respiration, and anomalous gene expression in experimental hepatomas: G.H.A. Clowes memorial lecture. , 1972, Cancer research.

[16]  P. Pedersen,et al.  Tumor mitochondria and the bioenergetics of cancer cells. , 1978, Progress in experimental tumor research.

[17]  P. Pedersen,et al.  Glucose catabolism in cancer cells: amplification of the gene encoding type II hexokinase. , 1996, Cancer research.

[18]  P. Pedersen,et al.  Intracellular localization and properties of particulate hexokinase in the Novikoff ascites tumor. Evidence for an outer mitochondrial membrane location. , 1983, The Journal of biological chemistry.

[19]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells , 1997, The Journal of Biological Chemistry.